HC Wainwright Predicts OmniAb’s Q1 Earnings (NASDAQ:OABI)

OmniAb, Inc. (NASDAQ:OABI) – HC Wainwright issued their Q1 2025 earnings estimates for shares of OmniAb in a research report issued on Wednesday, March 19th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.57) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.27) EPS.

Separately, Benchmark dropped their target price on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th.

OmniAb Trading Down 3.9 %

NASDAQ OABI opened at $2.44 on Monday. The stock’s fifty day moving average price is $3.31 and its 200-day moving average price is $3.74. The stock has a market cap of $344.57 million, a P/E ratio of -3.94 and a beta of -0.14. OmniAb has a 12 month low of $2.23 and a 12 month high of $5.54.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.13 million. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. During the same quarter in the prior year, the business posted ($0.14) EPS.

Insider Activity

In related news, CFO Kurt A. Gustafson sold 7,255 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $3.67, for a total value of $26,625.85. Following the completion of the sale, the chief financial officer now directly owns 206,211 shares of the company’s stock, valued at approximately $756,794.37. This represents a 3.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John L. Higgins purchased 125,750 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were acquired at an average cost of $2.35 per share, for a total transaction of $295,512.50. Following the completion of the acquisition, the director now owns 2,762,887 shares of the company’s stock, valued at approximately $6,492,784.45. This trade represents a 4.77 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 112,260 shares of company stock valued at $376,601 in the last ninety days. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OABI. Barclays PLC boosted its position in shares of OmniAb by 321.5% during the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after acquiring an additional 109,236 shares during the last quarter. FMR LLC raised its stake in OmniAb by 10.6% during the third quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after purchasing an additional 13,324 shares in the last quarter. Atria Investments Inc bought a new position in OmniAb during the third quarter valued at $148,000. Murchinson Ltd. purchased a new position in shares of OmniAb in the 3rd quarter worth $4,230,000. Finally, State Street Corp increased its holdings in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after buying an additional 34,654 shares during the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.